west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "杨秀芳" 3 results
  • 对焦虑症失眠患者的认知信念调查

    目的 了解焦虑症患者对睡眠的认知信念,为认知干预和临床护理提供基础信息。 方法 2011年4月-8月,利用睡眠个人信念与态度量表对50例焦虑症的失眠患者(研究组),以及50例一般睡眠障碍患者(对照组)进行量表测评。 结果 研究组患者的睡眠个人信念和态度得分明显低于对照组,其各因子分也明显低于对照组,差异有统计学的意义(P<0.01)。 结论 焦虑症患者比一般睡眠障碍者存在更多的错误认知和不合理的信念。

    Release date:2016-09-08 09:14 Export PDF Favorites Scan
  • ICU护士不良情绪相关因素分析

    目的 了解ICU护士的焦虑和抑郁、自尊状况,以便采取有效措施和方式减轻压力,使护士保持身心健康,从而提高ICU患者的抢救成功率和护理质量。 方法 2010年8月采用抑郁自评量表(SDS)、焦虑自评量表(SAS)和自尊量表(SES),对88名ICU护士进行问卷调查。 结果 不同因素对SAS、SDS、SES分值的影响为:女护士高于男护士;学历高的高于学历较低的;工龄长的高于工龄短的;年龄大的高于年龄小的。性别、年龄、工龄、受教育的程度对焦虑和抑郁、自尊的影响均有差异。 结论  ICU护士的SDS、SAS的分值较高,特别女性护士更为严重,在临床护理管理当中应给于更多的关注。

    Release date:2016-09-08 09:13 Export PDF Favorites Scan
  • Clinical Observation of Docetaxel Combined with Oxaliplatin Regimen for Advanced Gastric Cancer

    ObjectiveTo evaluate the efficacy and safety of docetaxel (DOC) combined with oxaliplatin (OXA) regimen in the treatment of advanced gastric cancer. MethodsSixty patients with advanced gastric cancer treated in our hospital from January 2008 to January 2011 were randomly divided into two groups. The treatment group (n=30) was given DOC combined with OXA regimen. Patients in this group were treated with DOC 75 mg/m2, ivgtt, d1; OXA 130 mg/m2, ivgtt, d4; with 21 days as a cycle. The control group (n=30) was given DCF regimen. Patients in the control group were treated with DOC 75 mg/m2, ivgtt, d1; cisplatin 75 mg/m2, ivgtt, d1; calcium folinate 200/m2, ivgtt, 2 h, d1-2; fluorouracil 400 mg/m2, bolus 10 minutes, fluorouracil 600 mg/m2 civ 22 h d1-2; also with 21 days as a cycle. All patients received two cycles of chemotherapy at least. The effective rate (complete remission+partial remission), adverse reactions, median survival time and quality of life were analyzed and compared between the two groups. ResultsThe effective rates in the treatment group and the control group were 60.0% and 46.7% respectively, showing a non-significant difference (P>0.05). The appetite increasing rate (70.0% vs 43.3%), the weight gain rate (60.0% vs 33.3%), and the Karnofsky score improvement rate (63.3% vs 30.0%) of the treatment group were significantly higher than those of the control group (P<0.05). The adverse reactions were fewer in the treatment group, and most of them were between grade Ⅰ and Ⅱ. The median time of disease progression (5.8 months vs 5.6 months) and the median survival period (11.8 months vs 9.2 months) of the treatment group were longer than those in the control group. ConclusionDOC combined with OXA regimen is effective in treating advanced gastric cancer. It can significantly improve the quality of life of the patients, and it has fewer adverse reactions. Meanwhile, the median survival period is prolonged. DOC combined with OXA regimen is worth to be applied in clinic.

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content